Volume 19 Supplement 1

35th International Symposium on Intensive Care and Emergency Medicine

Open Access

Tedizolid clearance by in vitro continuous renal replacement therapy model

  • SJ Lewis1,
  • L Switaj1 and
  • BA Mueller1
Critical Care201519(Suppl 1):P113

https://doi.org/10.1186/cc14193

Published: 16 March 2015

Introduction

Tedizolid is an oxazolidinone antibiotic approved to treat acute bacterial skin and soft tissue infection and is under investigation for treatment of nosocomial pneumonia, common in critically ill patients with acute kidney injury. There are limited data on tedizolid disposition in continuous renal replacement therapy (CRRT). This study's purpose was to assess continuous hemofiltration (CHF) and continuous hemodialysis (CHD) influence on tedizolid clearance.

Methods

Validated, bovine blood-based, in vitro CHF and CHD models were used with six new HF 1400 (polysulfone) and six new Multiflow 150 (AN 69) hemodiafilters. Tedizolid's transmembrane clearances (CLTM) during CHF and CHD were assessed by measuring sieving (SC) and saturation (SA) coefficients at various ultrafiltrate (Quf ) (1, 2, 3 l/ hour) and dialysate flow rates (Qd) (1, 2, 3 and 6 l/hour), using a blood flow rate (Qb) of 200 ml/minute. Tedizolid adsorption was tested in a 1 l recirculating CHF model at Quf of 2 l/hour and Qb of 200 ml/minute over 4 hours. Adsorption (%) was calculated after correcting for the dilution by CHF priming volume. Urea was added as a control in all experiments.

Results

Urea SC and SA were ~1 in all experiments. In CHF, mean tedizolid SC ranged from 0.52 to 0.57 for HF1400 and from 0.50 to 0.54 for M150. CLTM did not differ between filter types for Quf of 1, 2, and 3 l/hour. In CHD, mean tedizolid SA ranged from 0.46 to 0.56 for HF1400 and from 0.38 to 0.44 for M 150. Tedizolid CLTM with the HF1400 was higher than M150 values at Qd of 6 l/hours (P < 0.02). Tedizolid exhibited irreversible adsorption within 10 minutes. See Figure 1.

Figure 1

Conclusion

Tedizolid's CLTM is dependent on hemodiafilter type and Qd for CHD and Quf in CHF. At conventional CRRT rates, tedizolid CLTM appears modest relative to total body clearance and is unlikely to require dose adjustments. CRRT adsorption in the clinical setting is likely less than what we observed in this in vitro, continuously recirculating blood model.

Authors’ Affiliations

(1)
University of Michigan

Copyright

© Lewis et al.; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement